Abstract
Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with pamidronate. We retrospectively evaluated the incidences of ONJ and skeletal-related events (SRE) in 106 patients with multiple myeloma divided in two groups according to the schedule of administration of bisphosphonates: 51 received monthly administrations until tolerated (group A, standard schedule), 55 were treated monthly during the first year and then every 3 months (group B, reduced schedule). The incidence of SRE was similar (15.1 per 100 person years in group A and 17.7 in group B). ONJ occurred in seven patients, six in group A and one in group B (P=0.049). The risk of ONJ was eight-fold lower with the reduced schedule than with the standard schedule. The only significant risk factor for ONJ was the type of bisphosphonate (P=0.006). The incidence of ONJ was significantly higher with ZA than with pamidronate + ZA (9.1 vs 1.6 per 100 person-years). No ONJ was observed in patients treated only with pamidronate. A reduced schedule of ZA may be safer than the standard schedule while maintaining anti-resorptive efficacy.
Similar content being viewed by others
References
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.
Roodman GD . Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32: 290–292.
Coleman RE, Purohit OP . Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993; 19: 79–103.
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493.
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593–602.
Green JR, Muller K, Jaeggi KA . preclinical pharmacology of CGP 42'446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745–751.
Major PP, Coleman RE . Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol 2001; 28: 17–24.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003; 98: 1735–1744.
Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117.
Durie BG, Katz M, Crowley J . Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99–102.
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580–8587.
Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945–952.
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719–3736.
Lacy MQ, Dispensieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR et al. Mayo Clinic Consensus Statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047–1053.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Corso, A., Varettoni, M., Zappasodi, P. et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21, 1545–1548 (2007). https://doi.org/10.1038/sj.leu.2404682
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404682
- Springer Nature Limited
Keywords
This article is cited by
-
Prognosis by cancer type and incidence of zoledronic acid–related osteonecrosis of the jaw: a single-center retrospective study
Supportive Care in Cancer (2022)
-
Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen (2020)
-
Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma
Maxillofacial Plastic and Reconstructive Surgery (2017)
-
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients
Journal of Cancer Research and Clinical Oncology (2015)
-
Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?
Oral and Maxillofacial Surgery (2014)